TP53 and acute myeloid leukemia: Moreover, the ICC highlights molecular features in diagnosis and classification, introducing categories like MDS with mutated SF3B1 without excess blasts as MDS-SF3B1 regardless of RS percentage and MDS or MDS/AML with mutated TP53. It also introduces the concept of MDS/AML with MDS-related gene mutations.